Overview

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Status:
Completed
Trial end date:
2019-06-25
Target enrollment:
Participant gender:
Summary
This is a clinical study evaluating the efficacy and safety of rivipansel (GMI-1070) in treating subjects with sickle cell disease (SCD) who are 6 years of age or older experiencing a pain crisis necessitating hospitalization.
Phase:
Phase 3
Details
Lead Sponsor:
GlycoMimetics Incorporated
Pfizer